Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 17/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2818361 | 1.00 | KIF11 (0.43) | KIF11MMP13DNMT1 | |
| SCHEMBL20185747 | 0.88 | KIF11 (0.49) | KIF11DNMT1 | |
| SCHEMBL8370224 | 0.88 | KIF11 (0.49) | KIF11DNMT1 | |
| SCHEMBL21084958 | 0.88 | KIF11 (0.49) | KIF11DNMT1 | |
| SCHEMBL2820532 | 0.83 | FOLH1 (0.45) | KIF11 | |
| SCHEMBL2820537 | 0.83 | FOLH1 (0.45) | KIF11 | |
| SCHEMBL20202843 | 0.81 | KIF11 (0.48) | KIF11DNMT1 | |
| SCHEMBL23012930 | 0.79 | MMP13 (0.46) | MMP13 | |
| SCHEMBL7729230 | 0.79 | MMP13 (0.46) | MMP13 | |
| SCHEMBL7729226 | 0.79 | MMP13 (0.46) | MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659364-B2 | N-methyl-homocysteines and their use as well as process for their production | CIS BIO INTERNATIONAL (FR) | 2010-02-09 | — | — | US | disclosed |
| EP-1444194-B1 | N-METHYL-HOMOCYSTINES, USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | CIS BIO INT (FR) | 2009-12-09 | — | — | EP | disclosed |
| EP-1444194-A1 | N-METHYL-HOMOCYSTINES, USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-08-11 | — | — | EP | disclosed |
| US-20030120032-A1 | N-methyl-homocysteines and their use as well as process for their production | SCHERING AG (DE) | 2003-06-26 | — | — | US | disclosed |
| WO-2003042163-A1 | N-METHYL-HOMOCYSTINES, USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120032-A1 | N-methyl-homocysteines and their use as well as process for their production | BHMT, BHMT2, AHCY | KIF11 4731/4885MMP13 4335/4885DNMT1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.